[Multicenter clinical, double blind, and randomized study to assess the effectiveness and safety of binifibrate versus gemfibrozil in type IIa, IIb, and IV hyperlipidemia].
A multicentric, double-blind and randomized clinical study was conducted on a total of 54 patients with hyperlipidemias type IIa, IIb and IV in order to compare the effectivity and tolerance of two hyperlipemiant drugs: Binifibrate and Gemfibrozil. The treatment had a length of six months, performing clinical and analytical controls at: baseline, 1 month, 2 months, 4 months and 6 months. Both drugs showed a very good tolerance and the following results were obtained: Total cholesterol: Binifibrate -21.9%, Gemfibrozil -20.5%; Triglycerides: Binifibrate -48.6%, Gemfibrozil -43.27%; HDL: Binifibrate +18.2%, Gemfibrozil -12.8%; LDL: Binifibrate -24.3%, Gemfibrozil -22.8% VLDL: Binifibrate -48%, Gemfibrozil -43.2%; Apo A: Binifibrate +133.5%, Gemfibrozil +108.1%; Apo B: Binifibrate -59.7%, Gemfibrozil -46%. Both treatment were very effective, although the greater increase produced by Binifibrate on Chol-HDL, with a statistically significant difference versus the increase produced by Gemfibrozil, must be highlighted.
Corominas Vilardell
A
A
Servicio de Bioquímica, Hospital Germans Trias i Pujol de Badalona, Barcelona.
de Oya Otero
M
M
Escobar Jiménez
F
F
Anguera Vila
A
A
Ariño Armengol
B
B
D000293:Adolescent; D000328:Adult; D000368:Aged; D001059:Apoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000145:classification / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001059:Apoproteins; D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D014280:Triglycerides; D002784:Cholesterol; C038877:binifibrate; D015248:Gemfibrozil
Estudio clínico multicéntrico, doble ciego y randomizado para valorar la eficacia y tolerancia de binifibrato versus gemfibrozil en hiperlipidemias tipo IIa, IIb y IV.